黑素皮质素1受体信号对B细胞活化的负向调节可预防膜性肾病
研究在被动Heymann肾炎(PHN)大鼠模型中探究黑素皮质素1受体(MC1R)信号对体液免疫的调控作用。结果显示MC1R敲除加重PHN,表现为肾小球自体IgG和C5b-9沉积增加及循环自体IgG升高;黑素皮质素治疗改善野生型大鼠PHN,该疗效在敲除鼠中被削弱、经野生型骨髓来源细胞过继转移后恢复。机制上MC1R在B淋巴细胞表达并负向调控B细胞活化。
要点
- MC1R敲除加重被动Heymann肾炎,伴肾小球自体IgG和C5b-9沉积增加及循环自体IgG升高。
- 黑素皮质素治疗改善野生型大鼠PHN,疗效在MC1R敲除鼠中削弱、过继转移野生型骨髓来源细胞后恢复。
- MC1R激动以cAMP依赖方式诱导活化B细胞表达MITF并抑制IRF4,抑制浆细胞分化和IgG产生。
核心结论
- MC1R信号负向调节B细胞活化并在PHN中抑制体液免疫应答,提示MC1R信号可能为膜性肾病提供新的B细胞靶向治疗策略。
研究设计与样本
- 在野生型和MC1R敲除大鼠中诱导被动Heymann肾炎(PHN,膜性肾病模型),并给予黑素皮质素类药物处理。
- 处理药物包括长效促肾上腺皮质激素注射液、非类固醇性泛黑素皮质素受体激动剂[Nle4,DPhe7]-α-黑素细胞刺激素、选择性MC1R激动剂MS05、赋形剂凝胶或磷酸盐缓冲液。
- 另有大鼠预先接受来自野生型或MC1R敲除大鼠的同系骨髓来源细胞过继转移。
- 评估肾功能、组织学和分子变化。
主要发现
- MC1R敲除加重PHN,伴肾小球自体IgG和补体C5b-9沉积增加及循环自体IgG水平升高,提示体液免疫应答致敏。
- 黑素皮质素治疗改善野生型大鼠PHN,同时肾小球自体IgG和C5b-9沉积减少。
- 黑素皮质素的有益疗效在MC1R敲除大鼠中被削弱,但经野生型大鼠同系骨髓来源细胞过继转移后恢复。
- MC1R在B淋巴细胞中表达,并与B细胞活化呈负相关。
- MC1R激动以cAMP依赖方式触发活化B细胞中MITF表达,并抑制IRF4表达,导致浆细胞分化和IgG产生受抑。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
SIGNIFICANCE STATEMENT: Emerging evidence suggests that melanocortin neuropeptides-specifically adrenocorticotropic hormone-offer a novel, steroidogenic-independent therapeutic modality for membranous nephropathy (MN). The molecular mechanism underlying this beneficial effect, however, remains largely elusive. To investigate whether melanocortins modulate humoral immunity, the authors induced passive Heymann nephritis, a model of human MN, in wild-type and melanocortin 1 receptor (MC1R) knockout rats and treated them with melanocortin agents. Additional rats received adoptive transfer of bone marrow-derived cells beforehand from wild-type or MC1R knockout rats. The findings indicate that MC1R signaling plays a key role in negative modulation of B-cell activation and thereby suppresses humoral immune responses in passive Heymann nephritis, and suggest that MC1R signaling might offer a novel B cell-targeted therapeutic strategy for MN. BACKGROUND: Emerging evidence suggests that the pituitary neuropeptide melanocortins-specifically, adrenocorticotropic hormone-offer a novel nonsteroidogenic therapeutic modality for membranous nephropathy (MN). However, the mechanism(s) of action remains elusive. METHODS: To investigate whether melanocortins modulate humoral immunity, we induced passive Heymann nephritis (PHN), a model of MN, in wild-type (WT) and melanocortin 1 receptor (MC1R) knockout (KO) rats. We treated the animals with melanocortin agents-repository corticotropin injection, the nonsteroidogenic pan-melanocortin receptor agonist [Nle 4 , DPhe 7 ]-α-melanocyte stimulating hormone, the selective MC1R agonist MS05, vehicle gel, or phosphate-buffered saline-and evaluated kidney function, histology, and molecular changes. Additional rats received adoptive transfer of syngeneic bone marrow-derived cells beforehand from WT or MC1R KO rats. RESULTS: KO of MC1R worsened PHN and this was associated with increased deposition of autologous immunoglobulin G (IgG) and complement C5b-9 in glomeruli and higher circulating levels of autologous IgG-evidence of a sensitized humoral immune response. Melanocortin therapy ameliorated PHN in WT rats, coinciding with reduced glomerular deposition of autologous IgG and C5b -9. The beneficial efficacy of melanocortins was blunted in KO rats but restored by adoptive transfer of syngeneic bone marrow-derived cells derived from WT rats. Mechanistically, MC1R was expressed in B lymphocytes and was negatively associated with B cell activation. MC1R agonism triggered the expression of microphthalmia-associated transcription factor in activated B cells in a cAMP-dependent mode and also repressed the expression of interferon regulatory factor 4 (a lymphoid transcription factor essential for B-cell development and maturation), resulting in suppressed plasma cell differentiation and IgG production. CONCLUSIONS: MC1R signaling negatively modulates B cell activation and suppresses humoral immune responses in PHN, suggesting that MC1R signaling might offer a novel therapeutic target for MN.
引用
- Chen B, Guan X, Gunning WT, et al. Negative Modulation of B Cell Activation by Melanocortin 1 Receptor Signaling Protects against Membranous Nephropathy. J Am Soc Nephrol. 2022. PMID: 36446431. doi:10.1681/ASN.2022050605
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。